[go: up one dir, main page]

WO2009032172A3 - Platinum compositions as treatment for oct-related cancers - Google Patents

Platinum compositions as treatment for oct-related cancers Download PDF

Info

Publication number
WO2009032172A3
WO2009032172A3 PCT/US2008/010213 US2008010213W WO2009032172A3 WO 2009032172 A3 WO2009032172 A3 WO 2009032172A3 US 2008010213 W US2008010213 W US 2008010213W WO 2009032172 A3 WO2009032172 A3 WO 2009032172A3
Authority
WO
WIPO (PCT)
Prior art keywords
oct
platinum
treatment
related cancers
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/010213
Other languages
French (fr)
Other versions
WO2009032172A2 (en
Inventor
Stephen J Lippard
Katherine S Lovejoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of WO2009032172A2 publication Critical patent/WO2009032172A2/en
Publication of WO2009032172A3 publication Critical patent/WO2009032172A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer, in some cases, cancers which express an organic cation transporter (OCT). Some embodiments of the invention may comprise a compound including platinum (e.g., platinum(II) or platinum(IV)) and at least one organic ligand. In some embodiments, the compound may comprise an organic ligand which enhances interaction between the compound and an OCT.
PCT/US2008/010213 2007-08-31 2008-08-28 Platinum compositions as treatment for oct-related cancers Ceased WO2009032172A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96700707P 2007-08-31 2007-08-31
US60/967,007 2007-08-31

Publications (2)

Publication Number Publication Date
WO2009032172A2 WO2009032172A2 (en) 2009-03-12
WO2009032172A3 true WO2009032172A3 (en) 2009-05-07

Family

ID=40429603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010213 Ceased WO2009032172A2 (en) 2007-08-31 2008-08-28 Platinum compositions as treatment for oct-related cancers

Country Status (1)

Country Link
WO (1) WO2009032172A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9265747B2 (en) 2008-08-26 2016-02-23 Massachusetts Institute Of Technology Platinum (IV) complexes for use in dual mode pharmaceutical therapy
WO2012177935A1 (en) 2011-06-21 2012-12-27 Massachusetts Inistitute Of Technology Compositions and methods for the treatment of cancer
US8729286B2 (en) 2012-05-10 2014-05-20 Massachusetts Institute Of Technology Platinum compounds as treatment for cancers, and related methods, kits, and compositions
US9133225B2 (en) 2013-03-13 2015-09-15 Massachusetts Institute Of Technology Dual targeting anticancer agents
US9593139B2 (en) 2013-04-05 2017-03-14 Massachusetts Institute Of Technology Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety
US20180066004A9 (en) * 2014-04-08 2018-03-08 University Of Georgia Research Foundation, Inc. Mitochondria-targeting platinum(iv) prodrug
EP3777851B1 (en) * 2015-07-16 2022-12-28 Xomics Biopharma, Inc. Selective oct2 inhibitors for use in preventing toxicity of platinum drugs
US12453711B2 (en) * 2019-08-19 2025-10-28 Diverse Biotech, Inc. Platinum complex anti-neoplastic agents comprising a cannabinoid ligand

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679656B1 (en) * 1994-04-26 2001-09-05 Johnson Matthey Public Limited Company Improvements in platinum complexes
US20070082882A1 (en) * 2005-08-11 2007-04-12 Farrell Nicholas P Transplatinum complexes with N2O2 donor sets as cytotoxic and antitumor agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679656B1 (en) * 1994-04-26 2001-09-05 Johnson Matthey Public Limited Company Improvements in platinum complexes
US20070082882A1 (en) * 2005-08-11 2007-04-12 Farrell Nicholas P Transplatinum complexes with N2O2 donor sets as cytotoxic and antitumor agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAPP, T. ET AL.: "Dinuclear alkylamine platinum(II) complexes of [1,2-bis(4- fluorophenyl)ethylenediamine]platinum(II): influence of endocytosis and copper and organic cation transport systems on cellular uptake", CHEMMEDCHEM., vol. 1, no. 5, 2006, pages 560 - 564 *
YONEZAWA, A. ET AL.: "Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters(SLC22A1-3 and multidrug and toxin extrusion family)", J PHARMACOL EXP THER., vol. 319, no. 2, 2006, pages 879 - 886 *
ZHANG, S. ET AL.: "Organic cation transporters are determinants of oxaliplatin cytotoxicity", CANCER RES., vol. 66, no. 17, 2006, pages 8847 - 8857 *

Also Published As

Publication number Publication date
WO2009032172A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
TW200716141A (en) Compositions and methods for treatment for neoplasms
WO2009032172A3 (en) Platinum compositions as treatment for oct-related cancers
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2007141280A3 (en) Proteins
NO20076401L (en) Diarylhydantoinforbindelser
CY1118612T1 (en) METHODS AND CHEMICAL COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF PREVENTIVE INFECTIONS AND CANCER THROUGH 1-PD PROGRAM
SG164368A1 (en) Treatment of cancer
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
WO2008008923A3 (en) Compositions and methods for targeting cancer-specific transcription complexes
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2004098524A3 (en) Lipid platinum complexes and methods of use thereof
UA88638C2 (en) Beta-carbolines useful for treating inflammatory disease
WO2008022263A3 (en) Methods for lymph system imaging

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08829818

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08829818

Country of ref document: EP

Kind code of ref document: A2